Authors:
zur Stadt, U
Harms, DO
Schluter, S
Schrappe, M
Goebel, U
Spaar, H
Janka, G
Kabisch, H
Citation: U. Zur Stadt et al., MRD at the end of induction therapy in childhood acute lymphoblastic leukemia: outcome prediction strongly depends on the therapeutic regimen, LEUKEMIA, 15(2), 2001, pp. 283-285
Authors:
Brenner, H
Kaatsch, P
Burkhardt-Hammer, T
Harms, DO
Schrappe, M
Michaelis, J
Citation: H. Brenner et al., Long-term survival of children with leukemia achieved by the end of the second millennium, CANCER, 92(7), 2001, pp. 1977-1983
Citation: Do. Harms et Ge. Janka-schaub, Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92, LEUKEMIA, 14(12), 2000, pp. 2234-2239
Authors:
zur Stadt, U
Harms, DO
Schluter, S
Jorch, N
Spaar, HJ
Nurnberger, W
Volpel, S
Gutjahr, P
Schrappe, M
Janka, G
Kabisch, H
Citation: U. Zur Stadt et al., Minimal residual disease analysis in acute lymphoblastic leukemia of childhood after an induction therapy without asparaginase, KLIN PADIAT, 212(4), 2000, pp. 169-173
Authors:
Niehues, T
Kapaun, P
Harms, DO
Burdach, S
Kramm, C
Korholz, D
Janka-Schaub, G
Gobel, U
Citation: T. Niehues et al., A classification based on T cell selection-related phenotypes identifies asubgroup of childhood T-ALL with favorable outcome in the COALL studies, LEUKEMIA, 13(4), 1999, pp. 614-617
Authors:
Janka-Schaub, GE
Harms, DO
den Boer, ML
Veerman, AJP
Pieters, R
Citation: Ge. Janka-schaub et al., In vitro drug resistance as independent prognostic factor in study COALL-05-92 for treatment of childhood acute lymphoblastic leukemia: Basis for treatment stratification according to traditional risk factors and drug sensitivity in study COALL-06-97, KLIN PADIAT, 211(4), 1999, pp. 233-238